| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/02/2009 | US20090087405 Use of Lck inhibitors for treatment of immunologic diseases |
| 04/02/2009 | US20090087402 Cyclopropanated Macrocyclic Ketones and Lactones |
| 04/02/2009 | US20090087389 Dehydroepiandrosterone sulfate dihydrate inhalation compositions and methods |
| 04/02/2009 | US20090087388 Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| 04/02/2009 | US20090087387 (4aR,7S,7aR)-3-methoxy-4,7-dimethylhexahydrocyclopenta[c]pyran-1(3H)-one, useful as repellents for insects and arthropods |
| 04/02/2009 | US20090087384 Medicine and method for treatment of prostate cancer |
| 04/02/2009 | US20090085007 Ophthalmic composition for contact lens |
| 04/02/2009 | DE19940011B4 Alginataufbereitung und deren Verwendung Alginataufbereitung and their use |
| 04/02/2009 | DE112007001091T5 Pharmazeutische Formulierung in Form einer Salbe für die Behandlung von Tinea der Füße und Hände und Zubereitungsverfahren davon Pharmaceutical formulation in the form of an ointment for the treatment of tinea of the feet and hands, and preparation method thereof |
| 04/02/2009 | DE102008049320A1 Use of v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (HER2/neu) antagonists for treating restenosis after angioplasty or after placing a stent into a vessel |
| 04/02/2009 | DE102008013016A1 Verbindungen aus Myrothecium Sp. zur Hemmung des Krebszellwachstums Compounds from Myrothecium Sp. To inhibit cancer cell growth |
| 04/02/2009 | DE102007045476A1 Neue heteroarylsubstituierte Acetonderivate, geeignet zur Hemmung der Phospholipase A2 New heteroaryl acetone derivatives useful for inhibiting phospholipase A2 |
| 04/02/2009 | DE102007032507A1 Pyridazinonderivate Pyridazinone derivatives |
| 04/02/2009 | DE102004022392B4 Desinfektionsmittel-Zusammensetzung enthaltend zumindest eine Persäure-Verbindung und deren Verwendung zur Raum- und Luftdesinfektion Disinfectant composition containing at least a peracid compound and their use for the spatial and air disinfection |
| 04/02/2009 | DE10032137B4 Verfahren zur Herstellung von Phenothiazin-Granulat mit verbesserten Eigenschaften Process for the preparation of phenothiazine granules having improved properties |
| 04/02/2009 | CA2790774A1 Compositions comprising quinolone and methods for treating of controlling infections |
| 04/02/2009 | CA2709236A1 Pharmaceutical compositions of rhein or diacerein |
| 04/02/2009 | CA2704711A1 Thiazolopyrimidine p13k inhibitor compounds and methods of use |
| 04/02/2009 | CA2704710A1 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
| 04/02/2009 | CA2704132A1 Pharmaceutical composition containing esomeprazole |
| 04/02/2009 | CA2701110A1 Bicyclic .gamma.-amino acid derivative |
| 04/02/2009 | CA2701053A1 Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors |
| 04/02/2009 | CA2700979A1 Pyrimidine derivatives as protein kinase inhibitors |
| 04/02/2009 | CA2700922A1 .beta.-glucan treatment of upper respiratory tract infection symptoms and psychological well-being |
| 04/02/2009 | CA2700844A1 Stable imatinib compositions |
| 04/02/2009 | CA2700842A1 High concentration chitosan-nucleic acid polyplex compositions |
| 04/02/2009 | CA2700841A1 Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| 04/02/2009 | CA2700835A1 Solid forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use |
| 04/02/2009 | CA2700810A1 Immunoliposomes for treatment of cancer |
| 04/02/2009 | CA2700808A1 Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
| 04/02/2009 | CA2700797A1 Chromenone derivatives and their use for leukotriene biosynthesis inhibition |
| 04/02/2009 | CA2700673A1 Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| 04/02/2009 | CA2700665A1 Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2] |
| 04/02/2009 | CA2700664A1 Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists |
| 04/02/2009 | CA2700601A1 Use of a monoterpene to increase tissue repair |
| 04/02/2009 | CA2700596A1 Compound and use thereof in the treatment of amyloidosis |
| 04/02/2009 | CA2700591A1 Controlled release tamsulosin hydrochloride tablets and a process of making them |
| 04/02/2009 | CA2700539A1 Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor biological activity |
| 04/02/2009 | CA2700525A1 2-s-benzyl substituted pyrimidines as crth2 antagonists |
| 04/02/2009 | CA2700524A1 Alkylthio pyrimidines as crth2 antagonists |
| 04/02/2009 | CA2700489A1 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| 04/02/2009 | CA2700383A1 Urea-containing peptides as inhibitors of viral replication |
| 04/02/2009 | CA2700365A1 Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis |
| 04/02/2009 | CA2700295A1 Polo-like kinase inhibitors |
| 04/02/2009 | CA2700277A1 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives |
| 04/02/2009 | CA2700274A1 Quinone derivatives, pharmaceutical compositions, and uses thereof |
| 04/02/2009 | CA2700267A1 Azacytidine analogues and uses thereof |
| 04/02/2009 | CA2700242A1 Use of a combination of an opioid agonist and an opioid antagonist for the treatment of crohn's disease and the symptoms associated with crohn's disease |
| 04/02/2009 | CA2700227A1 Valomaciclovir polymorphs |
| 04/02/2009 | CA2700199A1 Combination therapy related to serotonin dual action compounds |
| 04/02/2009 | CA2700113A1 Indazole acrylic acid amide compound |
| 04/02/2009 | CA2700088A1 Quinolone derivative |
| 04/02/2009 | CA2700028A1 (carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament |
| 04/02/2009 | CA2700025A1 (cyclopropylphenyl)phenyloxamides, method for the production thereof, and use of same as a medicament |
| 04/02/2009 | CA2699787A1 (3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
| 04/02/2009 | CA2699773A1 Methods and compounds for treating retinol-related diseases |
| 04/02/2009 | CA2699718A1 Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
| 04/02/2009 | CA2699697A1 Quinoline derivatives as 5ht5a receptor antagonists |
| 04/02/2009 | CA2699614A1 Methods for promoting wound healing and muscle regeneration with the cell signaling protein nell1 |
| 04/02/2009 | CA2699607A1 Polo-like kinase inhibitors |
| 04/02/2009 | CA2699328A1 Pyrrolidines and piperidines as orexin receptor antagonists |
| 04/02/2009 | CA2697629A1 Molecular delivery vesicle |
| 04/02/2009 | CA2697583A1 Antidotes for factor xa inhibitors and methods of using the same |
| 04/02/2009 | CA2697580A1 Octahydropentalene compounds as chemokine receptor antagonists |
| 04/02/2009 | CA2697229A1 Galenical formulations of organic compounds |
| 04/02/2009 | CA2696113A1 Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| 04/01/2009 | EP2042606A1 Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic use |
| 04/01/2009 | EP2042599A1 Method of making microencapsulated DNA for vaccination and gene therapy |
| 04/01/2009 | EP2042510A2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleid acid (siNA) |
| 04/01/2009 | EP2042505A1 Polymorphic forms of a GABAa agonist |
| 04/01/2009 | EP2042504A1 Fused azole-pyrimidine derivatives |
| 04/01/2009 | EP2042503A1 Compound having acidic group which may be protected, and use thereof |
| 04/01/2009 | EP2042502A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| 04/01/2009 | EP2042500A1 N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors |
| 04/01/2009 | EP2042499A1 Salt of morpholine compound |
| 04/01/2009 | EP2042498A1 Crystal of benzoxadiazole derivative |
| 04/01/2009 | EP2042495A1 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 04/01/2009 | EP2042494A1 2,4,5-trisubstituted thiazole compounds,preparation methods, pharmaceutical compositions and medical uses thereof |
| 04/01/2009 | EP2042490A2 Benzimidazole derivatives as vanilloid receptor antagonists |
| 04/01/2009 | EP2042488A1 Matrix metalloproteinase inhibitors |
| 04/01/2009 | EP2042480A1 Aminoindan derivative or salt thereof |
| 04/01/2009 | EP2042184A1 Physiologically active polypeptide, polymer micelle having protein enclosed therein, and process for production of the polymer micelle |
| 04/01/2009 | EP2042182A1 Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| 04/01/2009 | EP2042181A1 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| 04/01/2009 | EP2042180A1 Preparations containing phytosterol |
| 04/01/2009 | EP2042179A1 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists |
| 04/01/2009 | EP2042178A1 Ocular formulations comprising 5-chlorouracil and use thereof |
| 04/01/2009 | EP2042177A1 Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease and the symptoms associated with Crohn's disease |
| 04/01/2009 | EP2042176A1 Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease |
| 04/01/2009 | EP2042175A1 Dose regimens of CB1-Receptor ligands in the treatment of obesity |
| 04/01/2009 | EP2042174A1 Adhesive preparation |
| 04/01/2009 | EP2042173A2 Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative |
| 04/01/2009 | EP2042172A1 Use of tocopherol derivatives as inhibitors of the notch signalling pathway |
| 04/01/2009 | EP2042171A1 Therapeutic or prophylactic agent for allergic dermatitis |
| 04/01/2009 | EP2042170A1 Creatine composition and use |
| 04/01/2009 | EP2042169A1 Controlled release tamsulosin hydrochloride tablets and a process of making them |
| 04/01/2009 | EP2042168A1 Inhalation device comprising phenethanolamine derivatives for treatment of respiratory diseases |
| 04/01/2009 | EP2042167A1 Use of a monoterpene to induce tissue repair |
| 04/01/2009 | EP2042164A1 Stabilized solid preparation |
| 04/01/2009 | EP2042163A1 Pharmaceutical compositions comprising fluvastatin |